{"id":"jdp-205-injection","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Rash"},{"rate":"5-10%","effect":"Pyrexia"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, JDP-205 Injection blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby releasing the brakes on T-cell activation and proliferation, leading to enhanced anti-tumor immune responses.","oneSentence":"JDP-205 Injection is a monoclonal antibody targeting the PD-1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:34.632Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT02024152","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics Trial of JDP-205 Injection 10 mg","status":"COMPLETED","sponsor":"JDP Therapeutics, Inc.","startDate":"2011-03","conditions":"Acute Urticaria","enrollment":24},{"nctId":"NCT02045524","phase":"PHASE1","title":"A Pilot Single Dose Crossover Pharmacokinetics Study Of JDP-205 Injection, 10 mg, In Healthy Male And Female Volunteers","status":"COMPLETED","sponsor":"JDP Therapeutics, Inc.","startDate":"2011-08","conditions":"Acute Urticaria","enrollment":4},{"nctId":"NCT02023164","phase":"PHASE3","title":"Pilot Phase III Clinical Trial of JDP-205 IV Injection for Treatment of Acute Urticaria","status":"COMPLETED","sponsor":"JDP Therapeutics, Inc.","startDate":"2013-07","conditions":"Acute Urticaria","enrollment":36},{"nctId":"NCT02935699","phase":"PHASE3","title":"Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria","status":"COMPLETED","sponsor":"JDP Therapeutics, Inc.","startDate":"2017-03-01","conditions":"Acute Urticaria","enrollment":262}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":595852,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cetirizine","Quzyttir"],"phase":"phase_3","status":"active","brandName":"JDP-205 Injection","genericName":"JDP-205 Injection","companyName":"JDP Therapeutics, Inc.","companyId":"jdp-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JDP-205 Injection is a monoclonal antibody targeting the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}